–
The manufacturing capacity of Novavax Inc is sufficient for the American demand for vaccines for the COVID-19 In 2021, which he estimates could be 500 million to 600 million doses, company executives said.
Novavax claimed last week that its vaccine The experimental drug produced high levels of antibodies against the new coronavirus, according to preliminary data from a small early-stage clinical trial.
Novavax expects to begin producing vaccines on a large scale in early 2021 and to be able to reach “more than” 2 billion doses of its vaccine annually, the executives added during a conference call with investors.
The company is still waiting for the AUnited States Food and Drug Administration (FDA) review the data from your early-stage study of your potential vaccine, but you have said you expect to begin a large Phase III trial in late September.
Novavax’s head of research Gregory Glenn told Reuters last week that the clinical trial in its last phase could collect enough data to get regulatory approvals starting in December.
–
